Truist upgraded Pacira (PCRX) to Buy from Hold with a price target of $30, up from $28. The firm, which thinks Pacira’s fundamental profile has “materially improved,” cites generic resolution on its lead asset, NOPAIN uptake plus the latest partnership with Johnson & Johnson (JNJ). The firm sees a “solid” buying opportunity, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira collabs with J&J’s MedTech to expand market reach of ZILRETTA
- Pacira Pharmaceuticals Implements Workforce Reduction for Efficiency
- Pacira Pharmaceuticals Secures New $300M Credit Facility
- Pacira debuts film spotlighting patient journey to pain relief
- Pacira Pharmaceuticals Stockholders Approve Amended Incentive Plan